A new call for new therapies to treat skin diseases has been launched by Spain-based global biopharmaceutical company Almirall, SA
This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The objective of this year’s edition is to find new partnership opportunities for active ingredients in preclinical or clinical development that can become new treatments for skin diseases.
Maribel Crespo, leader of AlmirallShare, said: “Since its launch five years ago, AlmirallShare has consolidated its position as a powerful channel for scientific exchange and cross-functional collaboration. This has allowed us to forge unique and valuable alliances with scientists that have led to long-term relationships. With this new call for proposals, we want to continue to foster scientific creativity by bringing together people and cultures from around the world to accelerate progress and stimulate the development of new dermatological medical solutions.
Proposals should focus on preclinical and clinical assets of any therapeutic modality, such as small molecules, biologics, or advanced therapies. The actives could have the potential to target immuno-inflammatory pathways for dermatological indications such as atopic dermatitis, hidradenitis suppurativa, alopecia areata or vitiligo.
Otherwise, they should be suitable for non-melanoma skin cancers such as basal and squamous cell carcinomas and cutaneous T-cell lymphomas, or for rare dermatological indications such as epidermolysis bullosa, pemphigus vulgaris, pemphigoid bullosa, among others. For preclinical actives, convincing evidence of in vitro and in vivo efficacy will be very valuable.
This year’s call is specifically aimed at scientists affiliated with start-ups, biotechnology companies, pharmaceutical companies, universities and research centers anywhere in the world, who can submit their proposals on sharedinnovation.almirall. com until October 31, 2022.
A team of scientific experts from Almirall will evaluate the submitted proposals to select those that best match the call requirements and have the potential to establish a long-term business partnership with the company.
AlmirallShare considers itself at the heart of research and was launched in 2017 as an open innovation Research and development platform designed to facilitate collaborations in dermatological research and find innovative solutions in medical dermatology.
This initiative attracted more than 1,100 scientists and received 560 proposals from 54 countries, proving to be a successful initiative that allowed Almirall to gain increasing recognition from the scientific community, raising the profile of the company. as a trusted partner for future collaborations.
The company, founded in 1943 and based in Barcelona, is listed on the Spanish Stock Exchange. Throughout its 79-year history, Almirall has always focused on patient needs.